NetScientific plc
Grant of Options to Director
London, UK – 8 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced that on 4 February 2016, options over a total of 200,000 ordinary shares of 5p each were granted to Francois Martelet.
|
Director |
Position |
Number of Options |
Number of Options |
|
Francois Martelet |
CEO |
200,000 |
559,020 |
The options have an exercise price of 86.2 pence per share being the average closing price for the ordinary shares over the five dealing days prior to the date on which the Option is granted. The options vest on the 4 February 2019, being the third anniversary from the date of Grant.
About NetScientific
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment.
For more information, please visit the website at www.netscientific.net.
Ends –
Contact Details
|
NetScientific François R. Martelet, M.D., CEO Mark Nanovich, Interim CFO |
Tel: +44 (0)20 3514 1800 |
|
Investec (NOMAD and broker) Gary Clarence / Daniel Adams |
Tel: +44 (0)20 7597 4000 |
|
Instinctif Partners Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest |
Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com |
END
RDSEVLFBQLFFBBB